Prelude Therapeutics CBO files initial Form 3 holdings

Prelude Therapeutics Inc executive Sean P. Brusky, Chief Business Officer, filed an initial ownership report showing his current equity position in the company.

Rhea-AI Filing Summary

Prelude Therapeutics Inc executive Sean P. Brusky, Chief Business Officer, filed an initial ownership report showing his current equity position in the company. He holds stock options over 300,000, 175,000 and 275,000 shares of common stock, each with a stated exercise price of $0.0000 per share and expirations in 2034, 2035 and 2036.

He also directly owns 100,000 shares of common stock. Footnotes explain these options were granted on May 1, 2024, February 4, 2025 and February 4, 2026 under the 2020 Equity Incentive Plan, with 25% vesting after one year and the remainder vesting monthly over the following three years, subject to his continued service.

Insider Trade Summary

4 transactions reported

Mixed 4 txns

Insider Brusky Sean P.

Role Chief Business Officer

Type	Security	Shares	Price	Value
holding	Employee Stock Option (Right to Buy)	--	--	--
holding	Employee Stock Option (Right to Buy)	--	--	--
holding	Employee Stock Option (Right to Buy)	--	--	--
holding	Common Stock	--	--	--

Holdings After Transaction: Employee Stock Option (Right to Buy) — 750,000 contracts (Direct); Common Stock — 100,000 shares (Direct)

Footnotes (3)

1. F1. Stock option grant awarded on May 1, 2024 under the 2020 Equity Incentive Plan. The stock option vests as to 25% of the total shares on May 1, 2025, and thereafter vests as to 1/48th of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
2. F2. Stock option grant awarded on February 4, 2025 under the 2020 Equity Incentive Plan. The stock option vests as to 25% of the total shares on February 4, 2026, and thereafter vests as to 1/48th of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
3. F3. Stock option grant awarded on February 4, 2026 under the 2020 Equity Incentive Plan. The stock option vests as to 25% of the total shares on February 4, 2027, and thereafter vests as to 1/48th of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Sean P. Brusky’s Form 3 filing for Prelude Therapeutics (PRLD) show?

The Form 3 shows Sean P. Brusky’s initial ownership in Prelude Therapeutics. He reports direct holdings of 100,000 common shares and several employee stock options granted under the 2020 Equity Incentive Plan with multi-year vesting schedules and long-dated expirations.

How many stock options does the Prelude Therapeutics (PRLD) Chief Business Officer report on Form 3?

Sean P. Brusky reports three employee stock option positions. These cover 300,000 shares expiring in 2034, 175,000 shares expiring in 2035, and 275,000 shares expiring in 2036, each referencing Prelude Therapeutics common stock as the underlying security.

What are the vesting terms of Sean P. Brusky’s stock options at Prelude Therapeutics (PRLD)?

Each option grant vests 25% of the shares one year after the grant date. The remaining 75% then vests in equal monthly installments over the next 36 months, contingent on Brusky continuing to provide service to Prelude Therapeutics on each vesting date.

What is the exercise price of the employee stock options reported by Sean P. Brusky at Prelude Therapeutics (PRLD)?

The filing lists an exercise price of $0.0000 per share for each employee stock option. This price applies to the options covering 300,000, 175,000, and 275,000 underlying shares of Prelude Therapeutics common stock disclosed in the ownership report.

When do Sean P. Brusky’s employee stock options at Prelude Therapeutics (PRLD) expire?

The reported stock options have long-term expiration dates. The grants tied to 300,000, 175,000, and 275,000 underlying common shares expire on April 30, 2034, February 3, 2035, and February 3, 2036, respectively, if not exercised or otherwise terminated earlier.

How many Prelude Therapeutics (PRLD) common shares does Sean P. Brusky directly own?

The ownership report indicates that Sean P. Brusky directly holds 100,000 shares of Prelude Therapeutics common stock. This position is separate from his employee stock options and is shown as a direct holding in the filing’s non-derivative securities section.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/19/2026 - 07:39 PM Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Brusky Sean P.

(Last) (First) (Middle)

C/O PRELUDE THERAPEUTICS INCORPORATED

175 INNOVATION BOULEVARD

(Street)

WILMINGTON DELAWARE 19805

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/05/2026

3. Issuer Name and Ticker or Trading Symbol
Prelude Therapeutics Inc [ PRLD ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Business Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	100,000	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Buy)	(1)	04/30/2034	Common Stock	300,000	$0	D
Employee Stock Option (Right to Buy)	(2)	02/03/2035	Common Stock	175,000	$0	D
Employee Stock Option (Right to Buy)	(3)	02/03/2036	Common Stock	275,000	$0	D

Explanation of Responses:

1. Stock option grant awarded on May 1, 2024 under the 2020 Equity Incentive Plan. The stock option vests as to 25% of the total shares on May 1, 2025, and thereafter vests as to 1/48th of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

2. Stock option grant awarded on February 4, 2025 under the 2020 Equity Incentive Plan. The stock option vests as to 25% of the total shares on February 4, 2026, and thereafter vests as to 1/48th of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

3. Stock option grant awarded on February 4, 2026 under the 2020 Equity Incentive Plan. The stock option vests as to 25% of the total shares on February 4, 2027, and thereafter vests as to 1/48th of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

Remarks:

Exhibit 24 - Power of Attorney

	/s/ Bryant Lim, as attorney-in-fact for the Reporting Person	03/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)